MX2020008120A - Metodos y composiciones para inhibir las actividades biologicas de adam9. - Google Patents

Metodos y composiciones para inhibir las actividades biologicas de adam9.

Info

Publication number
MX2020008120A
MX2020008120A MX2020008120A MX2020008120A MX2020008120A MX 2020008120 A MX2020008120 A MX 2020008120A MX 2020008120 A MX2020008120 A MX 2020008120A MX 2020008120 A MX2020008120 A MX 2020008120A MX 2020008120 A MX2020008120 A MX 2020008120A
Authority
MX
Mexico
Prior art keywords
adam9
biological activities
methods
compositions
modulating peptides
Prior art date
Application number
MX2020008120A
Other languages
English (en)
Inventor
Marcia L Moss
Robert Rasmussen
Chris Price
Original Assignee
Verra Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verra Therapeutics filed Critical Verra Therapeutics
Publication of MX2020008120A publication Critical patent/MX2020008120A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan péptidos moduladores de ADAM9 y métodos para usar los mismos para modular las actividades biológicas de ADAM9 in vitro y/o in vivo, para inhibir las actividades biológicas de ADAM9 asociadas con enfermedades o trastornos en los sujetos, para disminuir la inflamación, e inhibir la proliferación celular no deseada, la fibrosis, y la angiogénesis. En algunas realizaciones, los péptidos moduladores de ADAM9 incluyen modificaciones de uno o más aminoácidos de la secuencia de aminoácidos del prodominio de ADAM9 humano, y en algunas realizaciones, los péptidos moduladores de ADAM9 incluyen otras modificaciones tales como, pero sin limitación, la adición de grupos PEG.
MX2020008120A 2018-01-31 2019-01-31 Metodos y composiciones para inhibir las actividades biologicas de adam9. MX2020008120A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624491P 2018-01-31 2018-01-31
PCT/US2019/016015 WO2019152629A1 (en) 2018-01-31 2019-01-31 Methods and compositions for inhibiting adam 9 biological activities

Publications (1)

Publication Number Publication Date
MX2020008120A true MX2020008120A (es) 2020-09-18

Family

ID=67478593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008120A MX2020008120A (es) 2018-01-31 2019-01-31 Metodos y composiciones para inhibir las actividades biologicas de adam9.

Country Status (9)

Country Link
US (1) US20190382745A1 (es)
EP (1) EP3746112A4 (es)
JP (1) JP2021512596A (es)
CN (1) CN113286606A (es)
AU (1) AU2019215009A1 (es)
CA (1) CA3094136A1 (es)
IL (1) IL276359A (es)
MX (1) MX2020008120A (es)
WO (1) WO2019152629A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076701A1 (en) * 2019-10-17 2021-04-22 Trustees Of Boston University Methods and compositions relating to lung function
IL302066A (en) * 2020-10-14 2023-06-01 Univ Columbia Combined lipopeptide inhibitors as antivirals for SARS-COV-2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001280843B2 (en) * 2000-07-28 2006-12-07 Immunex Corporation A human disintegrin protein
US20040092466A1 (en) * 2002-11-11 2004-05-13 Isis Pharmaceuticals Inc. Modulation of ADAM9 expression
JP5328155B2 (ja) * 2005-02-02 2013-10-30 マクロジェニックス ウエスト， インコーポレイテッド Ａｄａｍ−９モジュレータ
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
US20130045244A1 (en) * 2010-02-11 2013-02-21 University Of Southern California Modified adam disintegrin domain polypeptides and uses thereof
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy

Also Published As

Publication number Publication date
US20190382745A1 (en) 2019-12-19
EP3746112A1 (en) 2020-12-09
JP2021512596A (ja) 2021-05-20
EP3746112A4 (en) 2021-10-20
IL276359A (en) 2020-08-31
WO2019152629A1 (en) 2019-08-08
CN113286606A (zh) 2021-08-20
CA3094136A1 (en) 2019-08-08
AU2019215009A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
Patil et al. Multilineage potential and proteomic profiling of human dental stem cells derived from a single donor
MX2021006856A (es) Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
ZA202002094B (en) Trispecific proteins and methods of use
MX2013013833A (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
EP4253406A3 (en) Novel polypeptides and medical uses thereof
MX2018011162A (es) Metodos de purificacion de colageno 7.
MX2020008120A (es) Metodos y composiciones para inhibir las actividades biologicas de adam9.
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
PH12017501070A1 (en) Peptides and their use in the treatment of skin
NZ801728A (en) Atf5 peptide variants and uses thereof
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MX2019009952A (es) Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas.
EA202090700A1 (ru) Компетентные по репликации аденовирусные векторы
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
WO2019077634A3 (en) Therapeutic compositions of antimicrobial peptides
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
MY189759A (en) Conjugate of finasteride with peptide
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr